Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)
Sponsor: Merck Sharp & Dohme LLC
Terminated
Study halted due to low recruitment. The 3 participants at time of termination transferred into study P04538 (NCT00727077). See NCT00727077 for details/results.
This observational or N/A phase trial investigates Hepatitis C and Hepatitis C, Chronic and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 13 recorded versions since 2006 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Terminated
-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jun 2022 — Jul 2024 [monthly]
Terminated
-
Dec 2021 — Jun 2022 [monthly]
Terminated
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
Feb 2017 — Aug 2017 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.